

### THE MOST INTENSIVELY STUDIED SLEEP MEDICATION

Efficacy of Dalmane (flurazepam HCl/Roche) has been documented in 9141 insomniac patients evaluated in 185 clinical studies. In addition, Dalmane efficacy has been proven in the sleep research laboratory during 995 subject nights.<sup>2</sup>

### WITH AN UNSURPASSED RECORD OF SAFETY


In a study of 2542 hospitalized medical patients with insomnia, adverse reactions were reported in only 3.1% or 78 patients. These reactions consisted predominantly of unwanted residual drowsiness; none were considered serious by attending physicians. Safety has also been demonstrated by lack of interference with many commonly ordered laboratory tests sand no unacceptable fluctuation in prothrombin time in patients on chronic warfarin therapy.

#### AND SLEEP WITHIN 17 MINU NO WORSENING OF SLEEP ON DISCONTINUATION

Rapid sleep induction, within 17 minutes on average, 3 sets the 5 for insomnia relief, with improvement that continues.

In reviewing the experience a discontinuation of Dalmane (flurazepam HCI/Roche) for per ranging up to 14 nights, no worsing of sleep compared with base was observed.

Should insomnia recur, the paramay require guidance in setting regular sleep program to help p



### 17 MINUT TINUATION

within 17 ets the state mprove

erie**nce** afk nane e) for periono:**w**orser with base!

ur, the pat in setting :: to help pro

4

otimum environment for of natural sleep. If hypnotis required, it should be the shortest time at the ective dose to achieve the


s receiving Dalmane am HCt Roche) should be i about possible combined th alcohol and other CNS ints, as well as about enhazardous occupations complete méntal alertness perating machinery or motor vehicle after ingesting

# DALMANE® flurazepam HCI/Roch

THE STANDARD OF HYPNOTIC EFFICACY FROM THE LEADER IN SLEEP RESEARCH



Please see following page for a summary of product information.



# SLEEP-SPECIFIC DALMANE® flurazepam HCI/Roche

One 15-mg capsule h.s.-recommended initial dosage for elderly or debilitated patients.
One 30-mg capsule h.s.-usual adult dosage (15 mg may suffice in some patients).

### THE STANDARD FOR HYPNOTIC EFFICACY WITH IMPORTANT ADDED BENEFITS

- Well tolerated<sup>2</sup>
- No chemical interference with many commonly ordered laboratory tests, including triglycerides, uric acid, glucose, SGOT, alkaline phosphatase and total protein<sup>45</sup> (See adverse reactions section of complete product information.)
- Compatible with chronic warfarin therapy; no unacceptable fluctuation in prothrombin time reported<sup>67</sup>

### UNLIKE NONSPECIFIC MEDICATIONS USED FOR SLEEP

#### Tricyclic antidepressants

- -which are not sleep specific,<sup>9</sup> yet are sometimes used in nondepressed patients for sleep
- -which can cause transient insomnia in the elderly10
- -which can require careful monitoring in cardiovascular patients<sup>10</sup>
- -which have strong anticholinergic effects10

#### **Antihistamines**

- -which are not reliable sleep-inducing agents"
- -which may produce stimulation instead"
- -which have anticholinergic effects"

#### **Major tranquilizers**

- -whose side effects may be troublesome for nonpsychotic patients<sup>12</sup>
- -where tolerance for sedation appears rapidly12

### Dalmane does not cause significant worsening of sleep beyond baseline levels upon discontinuation.8

References: 1. Kales A. et al.: J Clin Pharmacol 17:207-213. Apr 1977 2. Data on file, Medical Department. Hoffmann-La Roche Inc., Nutley NJ 3. Greenblatt DJ. Allen MD. Shader RI: Clin Pharmacol Ther 21:355-361. Mar 1977 4. Moore JD. Weissman L: J Clin Pharmacol 16:241-244. May-Jun 1976 5. Spiegel HE: Data on file. Medical Department. Hoffmann-La Roche Inc., Nutley NJ 6. Robinson DS. Amidon EL: Interaction of benzodiazepines with warfarin in man, in The Benzodiazepines, edited by Garattini S. Mussini E. Randall LO. New York, Raven Press, 1973, pp. 641-646 7. Warfarin Study: Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley NJ 8. Kales A., et al.: Clin Pharmacol Ther 18:356-363. Sep 1975 9. Baldessarini RJ: Drugs and the treatment of psychiatric disorders, chap. 19. in Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed 6-4New York, Macmillan Publishing Co. Inc., 1980, pp. 391-447 10. Cole JO. Davis JM. Antidepressant drugs, chap. 31.2, in Comprehensive Textbook of Psychiatry III. edited by Freedman AM, Kaplan HI. Sadock BJ, ed 2. Baltimore, The Williams & Wilkins Company, vol 2, 1976, pp. 1941-1956 11. Douglas WW: Histamine and 5-hydroxytryptamine (serotonin) and their antagonists, chap. 26, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed 6. New York, Macmillan Publishing Co. Inc., 1980, pp. 609-646 12. Davis JM. Cole JO: Antipsychotic drugs, chap. 31.1, in Comprehensive Textbook of Psychiatry/II. edited by Freedman AM, Kaplan HI. Sadock BJ, ed 2. Baltimore, The Williams & Wilkins Company, vol 2, 1976, pp. 1921-1940

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; in acute or chronic medical situations requiring restful sleep. Objective sleep laboratory data have shown effectiveness for at least 28 consecutive nights of administration. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended. Repeated therapy should only be undertaken with appropriate patient evaluation.

Contraindications: Known hypersensitivity to flurazepam HCl; pregnancy. Benzodiazepines may cause fetal damage when administered during pregnancy. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. An additive effect may occur if alcohol is consumed the day following use for nightlime sedation. This potential may exist for several days following discontinuation. Caution against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Potential impairment of performance of such activities may occur the day following ingestion. Not recommended for use in persons under 15 years of age. Though physical and psychological dependence have not been reported on recommended doses, abrupt discontinuation should be avoided with gradual tapering of dosage for those patients on medication for a prolonged period of time. Use caution in administering to addiction-prone individuals or those who might increase dosage.

**Precautions:** In elderly and debilitated patients, it is recommended that the dosage be limited to 15 mg to reduce risk of oversedation, dizziness, confusion and/or ataxia. Consider potential additive effects with other hypnotics or CNS depressants. Employ usual precautions in severely depressed patients, or in those with latent depression or suicidal tendencies, or in those with impaired renal or hepatic function.


Adverse Reactions: Dizziness, drowsiness, lightheadedness, staggering, ataxia and falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported. Also reported: headache. heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, Gl pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GU complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations and elevated SGOT, SGPT, total and direct bilirubins, and alkaline phosphatase, and paradoxical reactions, e.g., excitement, stimulation and hyperactivity.

**Dosage:** Individualize for maximum beneficial effect.

Adults: 30 mg usual dosage; 15 mg may suffice in some patients. Elderly of debilitated patients: 15 mg recommended initially until response is determined.

Supplied: Capsules containing 15 mg or 30 mg flurazepam HCI.





ponsible physicians know t despite sound medical judgnt and specialized skills, their conoses are often subject to certainty.

You must make allowances for ential adversity and you should bect your professional liability urance company to do the same. Responsible medical malpractice w that their policyholders' longge interests are best protected financial strength and solvency.

That's why we maintain the largest surplus of all the doctor-owned malpractice insurers in the western United States. That's why our earned premium to surplus ratio is the most favorable of all these companies. And that's why we continue to collect surplus contributions from new members.

Future results can't be guaranurers, like The Doctors' Company, teed, in the fragile art of medicine or in the volatile business of malpractice insurance. Our allowance for adversity is surplus.


For details about our program, call or write: The Doctors' Company, 233 Wilshire Blvd., Santa Monica, CA 90401 (213) 451-9936. Toll free, (800) 352-7271. Outside California, (800) 421-2368.

#### THE DOCTORS' COMPANY

AN INTERINSURANCE EXCHANGE OFFERING MEDICAL MALPRACTICE INSURANCE TO DOCTORS IN CALIFORNIA. NEVADA. WYOMING AND MONTANA



### An added complication... n the treatment of bacterial bronchitis\*



pult the package literature for prescribing

eations and Usage: Ceclor \* (cefactor, Lilly) is cated in the treatment of the following infections in caused by susceptible strains of the designated

roorganisms:
weet respiratory intections, including pneumona
sed by Streptococcus pneumoniae (Diplococcus
umoniae), Haemophilus influenzae, and S.
genes (group A beta-nemophilus isreptococci)
ppropriate culture and susceptibility studies
id be per formed to determine susceptibility of
tausative organism to Cector.

traindication: Ceclor is contraindicated in patients known allergy to the cephalosporin group of

MULICS.
MINDS PENICILLIN-SENSITIVE PATIENTS,
MALOSPORIN ANTIBIOTICS SHOULD BE ADMINISTERED
TIOUSLY. THERE IS CLINICAL AND LABORATORY
ENCE OF PARTIAL CROSS-ALLERGENICITY OF THE
DILLINS AND THE CEPHALOSPORINS. AND THERE ARE
ANCES IN WHICH PATIENTS HAVE HAD REACTIONS TO TUG CLASSES (INCLUDING ANAPHYLAXIS AFTER

THAL USE). ortics, including Ceclor, should be administered ly to any patient who has demonstrated some allergy, particularly to drugs.

autions: If an allergic reaction to cefactor occurs, rug should be discontinued, and, if necessary, the in should be treated with appropriate agents, e.g., sor amines, antihistamines, or corticosteroids, olonged use of cefactor may result in the growth of nonsusceptible organisms. Careful reaction of the patient is essential. If superinfection of the patient is essential. If superinfection of the patient is essential. 's during therapy, appropriate measures should

Its during therapy, appropriate measures should item. Strive direct Coombs tests have been reported by the combined of the com

Adverse Reactions: Adverse effects considered related to cefactor therapy are uncommon and are listed below: Gastrointestinal symptoms occur in about 2.5 percent of patients and include diarrhea (1 in 70) and nausea and vomitting (1 in 90).

Hypersensitivity reactions have been reported in about 1.5 percent of patients and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs tests each occur in less than 1 in 200 patients Cases of ser um-sickness-like reactions, including the above skin manifestations, fever, and arthraligivarithritis, have been reported. Anaphylaxis has also been reported.

Other effects considered related to therapy included eosinophilia (1 in 50 patients) and genital pruritus or vaginitis (less than 1 in 100 patients).

Causal Relationship Uncertain—Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.

Hepatic—Slight elevations in SCOT. SGPT, or alkaline phosphatase values (1 in 40).

Hematopovetic—Transient fluctuations in leukocyte count, predominantly hymphocytosis occurring in intents and young children (1 in 40).

Renal—Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200).

\*Many authorities attribute acute infectious Adverse Reactions: Adverse effects considered related

\*Many authorities attribute acute infectious exacerbation of chronic bronchitis to either *S. pneumoniae* or *H. influenzae*.\*

Note: Cector (cetaclor) is contraindicated in patients with known allergy to the cephalosporins and should be given cautiously to penicillin-allergic patients. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. See prescribing integration. information


- 1. Antimicrob. Agents Chemother., 8:91, 1975

- Antimicrob Agents Chemother. 6:91, 1975
   Antimicrob Agents Chemother. 71:470, 1977.
   Antimicrob Agents Chemother. 73:584, 1978.
   Antimicrob Agents Chemother. 12:490, 1977.
   Current Chemother any Ledited by W. Siegenthaler and R. Luthy), II: 880. Washington. D.C.: American Society for Microbiology, 1978.
   Antimicrob Agents Chemother. 13:861, 1978.
   Data on file. Eli Lilly and Company.

- Principles and Practice of Infectious Diseases (edited by G. L. Mandell, R. G. Douglas, Jr., and J. E. Bennett), p. 487. New York: John Wiley & Sons, 1979.



Additional information available to the profession on request from Eli Lilly and Company. Indianapolis. Indiana 46285. Eli Lilly Industries, Inc.
Carolina, Puerto Rico 00630



Everyone's talking about helping patients understand their prescription medication...

### with your help, Roche has been doing something about it



### WHAT IF

Roche Laboratories followed up the production and free distribution of 24 million copies of the Medication Education WHAT IF Book to patients via physicians, pharmacists and other health care professionals with a new series of booklets on important classes of medicines. The new booklets can be used with your patients to supplement your directions on

### HOW TO

- Use these classes of medicines appropriately
- Ensure maximum benefits from their proper use
- Avoid risks that can follow their misuse

Check below for free supply of booklets desired; complete coupon and mail to Professional Services Department, Roche Laboratories, Division of Hoffmann-La Roche Inc., Nutley, New Jersey 07110.

STATE

WHAT IF BOOK	HOW	HOW	HOW	HOW	HOW
	TO	TO	TO	TO	TO
	BOOK	BOOK	BOOK	GOOK	BOOK



Roche Laboratories Division of Hoffmann-LaRoche Inc. Nutley, New Jersey 07110 NAME

CITY

STREET ADDRESS

Medicines that matter from people who care

PRINTED IN U.S.A.

# HE HER!

# RU-TU Dispel the Clouds of Fall and

# **RU-TUSS**


Each prolonged action tablet contains: Phenylephiline Hydrochloride 25 mg

Phenylproponolamine Hydrochloride 50 mg
 Chlorohentramine Maleate 8 mg

 Hyoscyamine Sulfate 0.19 mg
 Atropine Sulfate 0.04
 Scopolamine Hydrobromide 0.01 mg . Each Ru-Tuss tablet acts continuously for 10 to 12 hours

## Symptomatic Relief of Sneezing and Nasal Congestion

Comprehensive decongesting, antihistaminic and anti-secretory reliever for patients with





# **RU-TUSS**

Each fluid ounce contains: Codeine Phosphate 65.8 mg • (WARNING: MAY BE HABIT FORMING) Phenylephrine Hydrochloride 30 mg • Phenylpropanolamine Hydrochloride 20 mg • Pheniramine Maleate 20 mg • Pyrtlamine Maleate 20 mg • Ammonium Chloride 200 mg • Alcohol 5%

### Symptomatic Relief of Coughing with Nasal and Bronchial **Decongestion**

Full range symptom-reliever for patients with air way congestion in the upper chest as well as the nose and throat.

- Blocks the cough Loosens mucus
- Reduces sneezing
   Eases breathing
  - Tasty, so it's easy to take





please consult complete product information, a summary of which follows:

Indications: Management of anxiety disorders. or short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Symptomatic relief of acute agitation, tremor, delirium tremens and hallucinosis due to acute alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to local pathology; spasticity caused by upper motor neuron disorders; athetosis; stiff-man syndrome: convulsive disorders (not for sole therapy). The effectiveness of Valium (diazepam/Roche) in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Contraindicated: Known hypersensitivity to the drug. Children under 6 months of age. Acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving appropriate therapy. Warnings: Not of value in psychotic patients. Caution against hazardous occupations requiring complete mental alertness. When used adjunctively in convulsive disorders. possibility of increase in frequency and/or severity of grand mal seizures may require increased dosage of standard anticonvulsant medication: abrupt withdrawal may be associated with temporary increase in frequency and/or severity of seizures. Advise against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms similar to those with barbiturates and alcohol have been observed with abrupt discontinuation, usually limited to extended use and excessive doses. Infrequently, milder withdrawal symptoms have been reported following abrupt discontinuation of benzodiazepines after continuous use. generally at higher therapeutic levels, for at least several months. After extended therapy, gradually taper dosage Keep addiction-prone individuals under careful surveillance because of their predisposition to habituation and dependence

Usage in Pregnancy: Use of minor tranquilizers during first trimester should almost always be avoided because of increased risk of congenital malformations as suggested in several studies. Consider possibility of pregnancy when instituting therapy; advise patients to discuss therapy if they intend to or do become pregnant.

Only Valium® (diazepam/Roche) is indicated in anxiety disorders and as an adjunct in the relief of skeletal

Precautions: If combined with other psychotropics or anticonvulsants. consider carefully pharmacology of agents employed: drugs such as phenothiazines. narcotics. barbiturates. MAO inhibitors and other antidepressants may potentiate its action. Usual precautions indicated in patients severely depressed, or with latent depression. or with suicidal tendencies. Observe usual precautions in impaired renal or hepatic function. Limit dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation.

The clearance of Valium (diazepam/Roche) and certain other benzodiazepines can be delayed in association with Tagamet (cimetidine) administration. The clinical significance of this is unclear.


Side Effects: Drowsiness. confusion. diplopia, hypotension. changes in libido. nausea. fatigue. depression. dysarthria. jaundice. skin rash. ataxia. constipation. headache. incontinence. changes in salivation. slurred speech. tremor. vertigo. urinary retention. blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety. hallucinations. increased muscle spasticity. insomnia, rage, sleep disturbances, stimulation have been reported; should these occur. discontinue drug. Isolated reports of neutropenia. jaundice: periodic blood counts and liver function tests advisable during long-term therapy.

**Dosage:** Individualize for maximum beneficial effect. *Adults:* Anxiety disorders, symptoms of anxiety. 2 to 10 mg b.i.d. to q.i.d.; alcoholism, 10 mg t.i.d. or q.i.d. in first 24 hours, then 5 mg t.i.d. or q.i.d. as needed: adjunctively in skeletal muscle spasm. 2 to 10 mg t.i.d. or q.i.d.; adjunctively in convulsive disorders. 2 to 10 mg b.i.d. to q.i.d. *Geriatric or debilitated patients:* 2 to 2½ mg. 1 or 2 times daily initially, increasing as needed and tolerated. (See Precautions.) *Children:* 1 to 2½ mg t.i.d. or q.i.d. initially, increasing as needed and tolerated (not for use under 6 months).

**How Supplied:** For oral administration, Valium scored tablets—2 mg. white: 5 mg. yellow; 10 mg. blue—bottles of 100\* and 500:\* Prescription Paks of 50, available in trays of 10.\* Tel-E-Dose\* packages of 100. available in trays of 4 reverse-numbered boxes of 25.† and in boxes containing 10 strips of 10.†

\*Supplied by Roche Products Inc., Manati, Puerto Rico 00701

<sup>†</sup> Supplied by Roche Laboratories. Division of Hoffmann-La Roche Inc..
Nutley. New Jersey 07110



# MINESMUSCIE

-Skeletal muscle relaxant

-Antianxietů

# Values of the second labels of

Indicated in anxiety disorders and as an adjunct in the relief of skeletal muscle spasm. Please see summary of product information on preceding page.

ROCHE